Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $81.2252W HIGH $166.25
Volume
2.23 M
Value Traded
145.46 M
Short % Float
5.6%
+3.05%Week
+20.87%1 Month
+35.99%3 Month
+69.8%6 Month
-34.65%5 Year
+2,826.79%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
17.14 B
EPS (TTM)
2.13
P/E Ratio
72.15
Ent. Value
19.32 B
Total Shares
111.53 M
Float Shares
111.06 M
Insiders
0.47%
Institutions
97.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RVTY Catalyst Timeline
Dated clinical, regulatory and corporate events for Revvity, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Revvity, Inc.
4Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2027Coverage
Past FDA Catalysts and PDUFA Decisions
How RVTY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Revvity, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RVTY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gonzales AnitaOfficer (VP and CAO) | Sell | -84 7,117 held | $155.48 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RVTY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RVTY for Q2 2026. | ||||
RVTY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RVTY ranks across every disease it competes in
Competitive Position is a premium feature
See how RVTY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRVTY News
RVTY▲ +0.2%today
Revvity to Host Investor Day
Revvity, Inc. has announced its 2026 Investor Day scheduled for November 13 at 9:00 a.m. ET. The event will feature presentations from senior management, focusing on the company's business initiatives, operational achievements, and financial outlook. Interested parties can register for the webcast, and a replay will be available afterward.
Read more →RVTYRevvity to Hold Earnings Call on November 3, 2026
Revvity, Inc. has announced the release of its third quarter 2026 financial results, which will occur before the market opens on November 3, 2026. The company will also host a conference call at 7:30 a.m. ET on the same day, featuring CEO Prahlad Singh and CFO Max Krakowiak to discuss the results. This event aims to provide insights to investors.
Read more →RVTY▲ +6%on this news
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
Revvity, Inc. has launched the GSP® T1D 3plex kit, an automated solution for detecting autoantibodies related to type 1 diabetes (T1D). This CE-IVDR-certified kit aims to facilitate population-wide screening, allowing for early identification of children at risk before symptoms manifest. The initiative addresses a significant public health challenge associated with T1D.
Read more →RVTYRevvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Revvity, Inc. has announced its acquisition of Human Cell Design, a biotechnology firm based in France. This strategic move aims to enhance Revvity's Life Sciences portfolio by integrating HCD's human pancreatic beta cell models. The acquisition will support drug discovery and preclinical research for metabolic diseases such as diabetes and obesity.
Read more →RVTYRevvity to Present at Upcoming Investor Conferences
Revvity, Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The presentations will feature key executives, highlighting the company's commitment to investor relations and transparency. These events are scheduled for September 2026.
Read more →RVTYRevvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
Revvity, Inc. has launched the SuperFlex prenatal screening system, which is CE-IVDR certified. This compact immunoassay instrument aims to provide reliable and rapid preeclampsia testing solutions for laboratories and clinics. The system is designed for lower-volume workflows, addressing the growing need for effective prenatal screening as preeclampsia rates rise globally.
Read more →RVTYRevvity Announces Financial Results for the Second Quarter of 2026
Revvity, Inc. reported its financial results for Q2 2026, showing a slight increase in GAAP earnings per share to $0.48 from $0.47 in the previous year. Revenue also rose to $730 million compared to $720 million in the same quarter last year. The company reported an operating income of $89 million.
Read more →RVTYRevvity Board Declares Quarterly Dividend
Revvity, Inc. has announced a quarterly dividend of $0.07 per share, payable on November 13, 2026. Shareholders of record as of October 23, 2026, will receive this dividend. This decision underscores Revvity's dedication to providing value to its shareholders.
Read more →RVTYRevvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs
Revvity, Inc. has announced the development of the T-SPOT™ A201, a high-throughput automated platform aimed at enhancing the accuracy and reliability of T-SPOT.TB™ testing in clinical labs. This innovation is particularly relevant for large-volume labs and addresses the growing demand for tuberculosis testing, driven by factors such as immigration screening and immunosuppressive therapy evaluations.
Read more →RVTYRevvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Revvity, Inc. has released its 2026 Impact Report, focusing on its sustainability and governance strategies. The report details the company's initiatives aimed at translating innovation into tangible benefits while promoting responsible business practices. CEO Prahlad Sin emphasizes the importance of combining scientific innovation with sustainability.
Read more →RVTYRevvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
Revvity, Inc. has launched a new program called Signals for Startups aimed at assisting emerging biotechnology companies. This initiative provides access to enterprise-grade Signals software along with guided onboarding and tailored configurations. The program is designed to help early-stage biotechs establish scalable informatics capabilities, fostering innovation from the outset.
Read more →RVTYRevvity to Hold Earnings Call on Tuesday, August 4, 2026
Revvity, Inc. (NYSE: RVTY) has announced the release of its second quarter 2026 financial results, scheduled for August 4, 2026. The company will hold a conference call at 7:30 a.m. ET on the same day to discuss these results. Key executives, including CEO Prahlad Singh and CFO Max Krakowiak, will lead the call.
Read more →RVTYRevvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
Revvity has announced an expansion of its Signals AI ecosystem through the integration of Anthropic Claude. This move is aimed at enhancing the capabilities of their AI offerings. The integration is expected to provide users with improved insights and analytics, although specific details on functionality remain limited.
Read more →RVTYRevvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
Revvity has introduced Signals AI, a new framework designed to accelerate scientific research and development. This innovative tool emphasizes privacy protection while enhancing the efficiency of R&D processes. The launch aims to provide researchers with advanced capabilities to drive scientific advancements.
Read more →RVTY▲ +6.7%on this news· ran to +17% by day 3
Revvity Announces Financial Results for the First Quarter of 2026
Revvity has announced its financial results for the first quarter of 2026. The details of the financial performance and any significant changes or highlights were not provided in the article. Further insights into revenue, expenses, and future outlook are expected in subsequent communications.
Read more →RVTYRevvity to Hold Earnings Call on Tuesday, May 5, 2026
Revvity, Inc. will announce its first quarter 2026 financial results on May 5, 2026, before market opening. A conference call will follow at 7:30 a.m. ET, hosted by CEO Prahlad Singh and CFO Max Krakowiak. The company continues to demonstrate growth, reporting $2.9 billion in revenue for 2025.
Read more →RVTYRevvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
Revvity, Inc. has launched its Signals BioDesign, a cloud-native molecular cloning solution aimed at enhancing biologics research workflows. This platform simplifies complex cloning processes and promotes collaborative development for biotech and pharma R&D teams. It integrates with existing systems to streamline therapeutic construct design and management, addressing the needs of researchers in developing advanced therapies.
Read more →About Revvity, Inc.
Headquarters77 4TH AVENUE, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next RVTY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime